The Cornell Clinical Trials Unit (CCTU) has enrolled patients at all stages of HIV disease from acute infection to advanced disease in over 150 clinical trials since its establishment in 1986. The CCTU is comprised of two sites: Upper East Side at 68th Street and York Avenue and in Chelsea at 53 West 23rd Street, 6th Floor. Director Dr. Marshall Glesby and Co-Director Dr. Kristen Marks lead the unit. Both sites share space with the Center for Special Studies at New York Presbyterian Hospital, a New York State Designated AIDS Care Center where HIV-infected patients receive their primary care.
The primary goal of the CCTU is to study the safety and efficacy of promising new treatments for people who are living with HIV. Through clinical trials, patients may gain access to new treatments not yet available to the general public. The information learned from these studies will ultimately improve the health of people who are living with HIV infection.
The CCTU is a member of the AIDS Clinical Trials Group (ACTG) and also participates in studies sponsored by the pharmaceutical industry and the New York City Department of Health (DOH). The CCTU is also a part of the HIV Prevention Trials Network (HPTN), a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of interventions designed to prevent the transmission of HIV. The HPTN strives to evaluate and implement cutting-edge biomedical, behavioral, and structural interventions to reduce the transmission of HIV. Additionally, the CCTU is part of the AIDS Malignancy Consortium (AMC) HPV Working Group, which seeks to improve the diagnosis and prevention of HPV-related disease and cancers that disproportionately affect persons with HIV.
To learn more about our current research studies, please see Our Current Research Studies, call us, or visit one of our locations.